Skip to main content
OpenTrials
Completed

NCT Number: NCT04156217

EBV-TCR-T Cells for EB Virus Infection After HSCT

This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of EBV-TCR-T cells in patients with EB virus infection after HSCT.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Hebei Yanda Ludaopei Hospital

Sanhe, Hebei, 065200, China

About this study

EBV infection is a common virus infection of HSCT, and which is highly related with the failure of transplantation and survival time of transplant patients. To evaluate the safety and efficacy of allogenic EBV-TCR-T cell therapy in subjects with EBV infection, patients with EBV emias or EBV positive PTLD will be enrolled, and donor derived EBV-TCR-T(HLA-A*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 EBV-TCR-T cells. The EBV DNA copies and EBV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 1-70 years, including boundary values, gender unlimited;
  • The EBV DNA copies number of allogenic HSCT patients with EBV infection (EBV emia and EBV positive PTLD) still did not decrease,after treated with lower dosage of Immunosuppressants,or antiviral therapy or Rituximab(Rituxan);
  • Allogenic HSCT patients could not tolerate the antiviral therapy and / or Rituximab(Rituxan);
  • The EBV-positive diagnosis criteria: EBV DNA copy number>1000 copies/ ml, or the tissue EBV-EBER pathological result is positive, the diagnosis of PTLD was based on the diagnostic criteria of WHO 2016;
  • Estimated life expectancy ≥ 3 months;
  • ECOG 3 ;
  • Patients who voluntarily sign informed consent and are willing to comply with treatment plans, visit arrangements, laboratory tests and other research procedures.

Exclusion criteria

  • Patients with active aGVHD III-IV and / or mild and severe cGVHD;
  • Received cell therapy such as DLI,CTL,CAR-T or participated in any other clinical study of drugs and medical devices before 30 days of enrollment;
  • Pregnant or lactating women;
  • Intracranial hypertension or confusion; respiratory failure; disseminated intravascular coagulation;
  • patients with organ failure:
  • Heart: NYHA heart function grade IV;
  • Liver: Grade C that achieves Child-Turcotte liver function grading;
  • Kidney: kidney failure and uremia;
  • Lung: symptoms of respiratory failure;
  • Brain: a person with a disability;
  • The researchers found that it was unsuitable for the recipients to be enrolled.

Treatment and study plan

EBV-TCR-T cells

Biological

EBV-TCR-T cells are prepared via lentiviral infection. patients with EBV emias or EBV positive PTLD will be enrolled, and donor derived EBV-TCR-T(HLA-A*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 EBV-TCR-T cells. The EBV DNA copies and EBV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).

Primary outcomes

  1. Percentage of adverse events

    Time frame: 3months

    Percentage of participants with adverse events.

Secondary outcomes

  1. Proliferation ratio of TCR-T cells

    Time frame: 3months

  2. changes of EBV-DNA copies

    Time frame: 3months

Sponsors and collaborators

Lead sponsor

Hebei Yanda Ludaopei Hospital

Other

Collaborators

  • China Immunotech (Beijing) Biotechnology Co., Ltd.

Registry information

Official study title

A Pilot Study of EBV-TCR-T Cells in EB Virus Infection Diseases After HSCT

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Nov 7, 2019
Registry last updated
Mar 8, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.